Loading...
•
Sep 30, 2023
Protagonist Q3 2023 Earnings Report
Reported third quarter financial results and provided a corporate update.
Key Takeaways
Protagonist Therapeutics reported positive Phase 2b data from the FRONTIER 1 study with JNJ-2113 and continued to make progress with rusfertide in the Phase 3 VERIFY study. The company anticipates sharing latest findings at the ASH2023 Annual Meeting.
Five rusfertide abstracts accepted for oral and poster presentations at the 65th ASH Annual Meeting and Exposition (ASH2023)
Positive topline results from the Phase 2b FRONTIER 1 study of JNJ-2113 (formerly PN-235) presented in July 2023
JNJ-2113 clinical development program advances with two Phase 3 studies in moderate-to-severe psoriasis and a Phase 2b study in moderately-to-severely active ulcerative colitis (UC) commencing in Q4 2023
Forecast cash runway through Q1 2026
Forward Guidance
Protagonist Therapeutics is focused on advancing the clinical development of JNJ-2113 and rusfertide.
Positive Outlook
- JNJ-2113 Phase 3 studies in psoriasis commencing.
- JNJ-2113 Phase 2b study in ulcerative colitis commencing.
- Additional Phase 3 studies in psoriasis expected to begin in Q1 2024.
- Rusfertide Phase 3 VERIFY study ongoing.
- Rusfertide abstracts accepted for presentation at ASH2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...